<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02585960</url>
  </required_header>
  <id_info>
    <org_study_id>261303</org_study_id>
    <nct_id>NCT02585960</nct_id>
  </id_info>
  <brief_title>BAX 855 PK-Guided Dosing</brief_title>
  <official_title>Phase 3, Prospective, Randomized, Multi-center Clinical Study Comparing the Safety and Efficacy of BAX 855 Following PK-guided Prophylaxis Targeting Two Different FVIII Trough Levels in Subjects With Severe Hemophilia A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To compare the efficacy and safety of PK-guided treatment with BAX 855 targeting FVIII
           trough levels of 1-3% and approximately 10% (8-12%)

        2. To further characterize pharmacokinetic (PK) and pharmacodynamic (PD) parameters of BAX
           855
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 21, 2015</start_date>
  <completion_date type="Anticipated">August 13, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 13, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence or absence of any bleedings in the second 6-month study period</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total, spontaneous and traumatic Annualized Bleeding Rate (ABR), and spontaneous Annualized Joint Bleeding Rate (AJBR)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total weight-adjusted consumption of BAX 855</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall hemostatic efficacy rating at 8 ± 1 hour after the initiation of treatment and at resolution of bleed</measure>
    <time_frame>8 ± 1 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of BAX 855 infusions needed for the treatment of bleeding episodes</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemophilia Joint Health Score (HJHS)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-, post- and perioperative hemostatic efficacy in case of surgery assessed by a four-point ordinal scale (excellent - good - fair - none)</measure>
    <time_frame>Day 0 through discharge or 14 days post-surgery, whichever is first</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra- and postoperative blood loss in case of surgery</measure>
    <time_frame>Day 0 through discharge or 14 days post-surgery, whichever is first</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Adverse Events (AEs) and non-Serious Adverse Events (SAEs)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in vital signs and clinical laboratory parameters (hematology, clinical chemistry, and lipids)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inhibitory antibodies to FVIII, and binding antibodies to FVIII, BAX 855, PEG, and CHO protein</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcomes: Physical domain and component scores of the SF-36 Health Survey</measure>
    <time_frame>Screening visit through study completion visit at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area under the plasma concentration versus time curve (AUC0-∞)</measure>
    <time_frame>Within 30 minutes prior to infusion; and 15 - 30 minutes, and 3, 8, 24, 48, 72, and 96 hours post-infusion</time_frame>
    <description>Area under the plasma concentration versus time curve from time 0 to infinity. BAX 855 PK parameters based on FVIII activity at baseline and steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Incremental recovery (IR)</measure>
    <time_frame>Within 30 minutes prior to infusion; and 15 - 30 minutes post-infusion</time_frame>
    <description>BAX 855 PK parameters based on FVIII activity at baseline and steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Plasma half-life (T-1/2)</measure>
    <time_frame>Within 30 minutes prior to infusion; and 15 - 30 minutes, and 3, 8, 24, 48, 72, and 96 hours post-infusion</time_frame>
    <description>BAX 855 PK parameters based on FVIII activity at baseline and steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Mean Residence Time (MRT)</measure>
    <time_frame>Within 30 minutes prior to infusion; and 15 - 30 minutes, and 3, 8, 24, 48, 72, and 96 hours post-infusion</time_frame>
    <description>BAX 855 PK parameters based on FVIII activity at baseline and steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Within 30 minutes prior to infusion; and 15 - 30 minutes, and 3, 8, 24, 48, 72, and 96 hours post-infusion</time_frame>
    <description>BAX 855 PK parameters based on FVIII activity at baseline and steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Time to Maximum Concentration in Plasma (Tmax)</measure>
    <time_frame>Within 30 minutes prior to infusion; and 15 - 30 minutes, and 3, 8, 24, 48, 72, and 96 hours post-infusion</time_frame>
    <description>BAX 855 PK parameters based on FVIII activity at baseline and steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Clearance (CL)</measure>
    <time_frame>Within 30 minutes prior to infusion; and 15 - 30 minutes, and 3, 8, 24, 48, 72, and 96 hours post-infusion</time_frame>
    <description>BAX 855 PK parameters based on FVIII activity at baseline and steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Volume of distribution at steady state (Vss)</measure>
    <time_frame>Within 30 minutes prior to infusion; and 15 - 30 minutes, and 3, 8, 24, 48, 72, and 96 hours post-infusion</time_frame>
    <description>BAX 855 PK parameters based on FVIII activity at baseline and steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Incremental recovery (IR) Over Time</measure>
    <time_frame>Within 30 minutes prior to infusion; and 15 - 30 minutes post-infusion at Study Visits- Baseline; and Month 3, 6, 9, and 12</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Pharmacokinetic (PK) evaluation of BAX 855</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will first undergo an initial pharmacokinetic (PK) assessment. Following the PK assessment participants will be randomized to one of 2 dosing regimens.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Twice Weekly Dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard treatment arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Every Other Day Dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intensified treatment arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PEGylated Recombinant Factor VIII</intervention_name>
    <description>Pharmacokinetic (PK) evaluation</description>
    <arm_group_label>Pharmacokinetic (PK) evaluation of BAX 855</arm_group_label>
    <other_name>BAX855</other_name>
    <other_name>BAX 855</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PEGylated Recombinant Factor VIII</intervention_name>
    <description>Standard treatment</description>
    <arm_group_label>Twice Weekly Dosing</arm_group_label>
    <other_name>BAX 855</other_name>
    <other_name>BAX855</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PEGylated Recombinant Factor VIII</intervention_name>
    <description>Intensified treatment</description>
    <arm_group_label>Every Other Day Dosing</arm_group_label>
    <other_name>BAX855</other_name>
    <other_name>BAX 855</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Participants transitioning from another BAX 855 study who meet ALL of the following
             criteria are eligible for this study:

               1. Participant has completed the end of study visit of a BAX 855 study or is
                  transitioning from the ongoing Baxalta Continuation Study 261302.

               2. Participant is either receiving on-demand treatment or prophylactic treatment
                  with BAX 855 and had an Annual Bleed Rate (ABR) of ≥ 2 documented and treated
                  during the past 12 months.

               3. Participant is human immunodeficiency virus negative (HIV-); or HIV+ with stable
                  disease and CD4+ count ≥ 200 cells/mm^3, as confirmed by central laboratory.

               4. Participant is willing and able to comply with the requirements of the protocol.

          -  Newly recruited participants (ie not transitioning from another BAX 855 study)
             including BAX855 naïve participants who meet ALL of the following criteria are
             eligible for this study:

               1. Participant has severe hemophilia A (FVIII clotting activity &lt; 1%) as confirmed
                  by central laboratory or by historically documented FVIII clotting activity
                  performed by a certified clinical laboratory and/or a FVIII gene mutation
                  consistent with severe hemophilia A

               2. Participant has been previously treated with plasma-derived FVIII concentrates or
                  recombinant FVIII for ≥ 150 documented exposure days (EDs)

               3. Participant is either receiving on-demand treatment or prophylactic treatment and
                  had an annual bleeding rate of ≥ 2 documented and treated during the past 12
                  months.

               4. Participant has a Karnofsky performance score of ≥ 60 at screening

               5. Participant is HIV-; or HIV+ with stable disease and CD4+ count ≥ 200 cells/mm^3,
                  as confirmed by central laboratory at screening

               6. Participant is hepatitis C virus negative (HCV-) by antibody (if positive,
                  additional PCR testing will be performed), as confirmed by central laboratory at
                  screening; or HCV+ with chronic stable hepatitis

               7. If female of childbearing potential, participant presents with a negative urine
                  pregnancy test and agrees to employ adequate birth control measures for the
                  duration of the study

               8. Participant is willing and able to comply with the requirements of the protocol.

        EXCLUSION CRITERIA:

          -  Participants transitioning from another BAX 855 study who meet ANY of the following
             criteria are not eligible for this study:

               1. Participant has developed a confirmed inhibitory antibody to FVIII with a titer
                  of ≥ 0.6 BU using the Nijmegen modification of the Bethesda assay as determined
                  at the central laboratory during the course of the previous BAX 855 study.

               2. Participant has been diagnosed with an acquired hemostatic defect other than
                  hemophilia A.

               3. The participant's weight is &lt; 35 kg or &gt; 100 kg.

               4. Participant's platelet count is &lt; 100,000/mL.

               5. Participant has an abnormal renal function (serum creatinine &gt; 1.5 times the
                  upper limit of normal).

               6. Participant has active hepatic disease with alanine aminotransferase (ALT) or
                  aspartate aminotransferase (AST) levels ≥ 5 times the upper limit of normal.

               7. Participant is scheduled to receive a systemic immunomodulating drug (e.g.
                  corticosteroid agents at a dose equivalent to hydrocortisone greater than 10
                  mg/day, or α-interferon) other than anti-retroviral chemotherapy during the
                  study.

               8. Participant has a clinically significant medical, psychiatric, or cognitive
                  illness, or recreational drug/alcohol use that, in the opinion of the
                  investigator, would affect participant's safety or compliance.

               9. Participant is planning to take part in any other clinical study during the
                  course of the study.

              10. Participant is a member of the team conducting this study or is in a dependent
                  relationship with one of the study team members. Dependent relationships include
                  close relatives (ie, children, partner/spouse, siblings, parents) as well as
                  employees of the investigator or site personnel conducting the study.

        Newly recruited participants (ie not transitioning from another BAX 855 study) who meet ANY
        of the following criteria are not eligible for this study:

          1. Participant has detectable FVIII inhibitory antibodies (≥ 0.6 BU using the Nijmegen
             modification of the Bethesda assay) as confirmed by central laboratory at screening.

          2. Participant has a history of confirmed FVIII inhibitors with a titer ≥ 0.6 Bethesda
             Units (BU) (as determined by the Nijmegen modification of the Bethesda assay or the
             assay employed with the respective cut-off in the local laboratory) at any time prior
             to screening.

          3. Participant has been diagnosed with an inherited or acquired hemostatic defect other
             than hemophilia A (eg, qualitative platelet defect or von Willebrand's disease).

          4. The participant's weight is &lt; 35 kg or &gt; 100 kg.

          5. Participant's platelet count is &lt; 100,000/mL.

          6. Participant has known hypersensitivity towards mouse or hamster proteins, PEG or Tween
             80.

          7. Participant has severe chronic hepatic dysfunction [eg, ≥ 5 times upper limit of
             normal alanine aminotransferase (ALT) or aspartate aminotransferase (AST), as
             confirmed by central laboratory at screening, or a documented INR &gt; 1.5].

          8. Participant has severe renal impairment (serum creatinine &gt; 1.5 times the upper limit
             of normal).

          9. Participant has current or recent (&lt; 30 days) use of other pegylated drugs prior to
             study participation or is scheduled to use such drugs during study participation.

         10. Participant is scheduled to receive during the course of the study, a systemic
             immunomodulating drug (e.g. corticosteroid agents at a dose equivalent to
             hydrocortisone greater than 10 mg/day, or α-interferon) other than anti-retroviral
             chemotherapy.

         11. Participant has participated in another clinical study involving an IP or
             investigational device within 30 days prior to enrollment or is scheduled to
             participate in another clinical study involving an IP or investigational device during
             the course of this study.

         12. Participant has a medical, psychiatric, or cognitive illness or recreational
             drug/alcohol use that, in the opinion of the investigator, would affect participant
             safety or compliance.

         13. Participant is a member of the team conducting this study or is in a dependent
             relationship with one of the study team members. Dependent relationships include close
             relatives (ie, children, partner/spouse, siblings, parents) as well as employees of
             the investigator or site personnel conducting the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Savage, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Baxalta now part of Shire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phoenix Childrens Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016-7710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Hemophilia &amp; Thrombosis Center, located within The University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University-ECC</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville KCPCRU</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-5456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gulf States Hemophilia Centre</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Perth Blood Institute</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH - Medizinische Universität Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT &quot;Sv. Georgi&quot;, EAD</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT 'Tsaritsa Yoanna - ISUL', EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT 'Sv. Marina', EAD, Clinic of Clinical Hematology</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nice- Service hematologie</name>
      <address>
        <city>Nice</city>
        <state>Alpes Maritimes</state>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Morvan</name>
      <address>
        <city>Brest Cedex</city>
        <state>Finistere</state>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rennes - Hopital Pontchaillou</name>
      <address>
        <city>Rennes cedex 09</city>
        <state>Ille Et Vilaine</state>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Caen - Hôpital Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HZRM Hamophilie Zentrum Rhein Main GmbH</name>
      <address>
        <city>Moerfelden-Walldorf</city>
        <state>Hessen</state>
        <zip>65446</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inst. f. Experimentelle Hamatologie u. Transfusionsmedizin</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhein Westfalen</state>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>COAGULATION RESEARCH CENTRE GmbH</name>
      <address>
        <city>Duisburg</city>
        <state>Nordrhein Westfalen</state>
        <zip>47051</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamophiliezentrum/Gerinnungssprechstunde</name>
      <address>
        <city>Berlin</city>
        <zip>10249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MVZ Labor Dr. Reising-Ackermann</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Shatin</city>
        <zip>00000</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magyar Honvedseg EK</name>
      <address>
        <city>Budapest</city>
        <zip>1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DE OEC Belgyógyászati Int</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PTE ÁOK</name>
      <address>
        <city>Pecs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Hashomer</city>
        <zip>5262000</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UOC Ematologia, Azienda ULSS 8 Asolo, Regione Veneto</name>
      <address>
        <city>Castelfranco Veneto</city>
        <state>Treviso</state>
        <zip>31033</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Osped. Ferrarotto</name>
      <address>
        <city>Catania</city>
        <zip>90124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Umberto I Pol. di Roma-Università di Roma La Sapienza</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A. Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Citta della Salute e della Scienza - Presidio Molinette</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ULSS n. 6 &quot;Vicenza&quot;</name>
      <address>
        <city>Vicenza</city>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ampang</name>
      <address>
        <city>Ampang</city>
        <state>Kuala Lumpur</state>
        <zip>68000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Queen Elizabeth</name>
      <address>
        <city>Kota Kinabalu</city>
        <state>Sabah</state>
        <zip>88586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Kuala Lumpur</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Melaka</name>
      <address>
        <city>Melaka</city>
        <zip>75400</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pulau Pinang</name>
      <address>
        <city>Pulau Pinang</city>
        <zip>10450</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo Universitetssykehus HF</name>
      <address>
        <city>Oslo</city>
        <zip>0372</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny im. Mikolaja Kopernika, Klinika Hematologii</name>
      <address>
        <city>Lodz</city>
        <zip>93-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alvamed</name>
      <address>
        <city>Poznań</city>
        <zip>61-828</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Hematologii Ii Transfuzjologii</name>
      <address>
        <city>Warszawa</city>
        <zip>02-776</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SP Szpital Kliniczny Nr 1 we Wroclawiu</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-367</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta Brasov</name>
      <address>
        <city>Brasov</city>
        <zip>500365</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul Oncologic ClNa.</name>
      <address>
        <city>Cluj Napoca</city>
        <zip>400124</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Singapore General Hospital- Parent</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KK Women's And Children's Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>229899</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Baleares</state>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <state>La Coruña</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Malaga</name>
      <address>
        <city>Malaga</city>
        <state>Málaga</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhuset</name>
      <address>
        <city>Gothenburg</city>
        <zip>S-41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11490</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acibadem Hastanesi</name>
      <address>
        <city>Adana</city>
        <zip>01130</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akdeniz University</name>
      <address>
        <city>Antalya</city>
        <zip>07070</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul University</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege University</name>
      <address>
        <city>Izmir</city>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NChSH Okhmatdyt of MoHU Center of Children Oncohematology and Bone Marrow Transplantation</name>
      <address>
        <city>Kyiv</city>
        <zip>1135</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyiv CCH #9 Dept of Surgery City SPC of Diagnostics &amp; Treatment of Patients with HP</name>
      <address>
        <city>Kyiv</city>
        <zip>4112</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SI Institute of Blood Pathology and Transfusion Medicine of NAMSU</name>
      <address>
        <city>Lviv</city>
        <zip>79044</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.V. Sklifosovskyi Poltava RCH Dept of Gematology HSEIU Ukrainian Medical Stomatological Academy</name>
      <address>
        <city>Poltava</city>
        <zip>36011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Hospital for Children</name>
      <address>
        <city>Bristol</city>
        <state>Avon</state>
        <zip>BS2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <state>Leicestershire</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <state>West Glamorgan</state>
        <zip>CF14 4XN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Malaysia</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2015</study_first_submitted>
  <study_first_submitted_qc>October 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2015</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

